|
|
||||||||
Phytonutrients Laboratory, BHNRC, ARS, USDA, Beltsville, Maryland, USA
1Correspondence: Jae B. Park, Ph.D., Phytonutrients Laboratory, Bldg. 307C, Rm. 131, BHNRC, ARS, USDA, Beltsville, MD 20705, USA. E-mail: parkj{at}ars.usda.gov
N-Caffeoyldopamine is a phytochemical found in various plants, including cocoa (Theobroma cacao L.). N-caffeoyldopamine and its natural analogs (N-cinnamoyldopamine, N-coumaroyldopamine, N-feruloyldopamine, and N-sinapoyldopamine) were synthesized and investigated to determine their potency as ß-adrenoceptor agonists, because they have chemical structural moieties found in ß-adrenoceptor agonists. Among the compounds tested in this study, N-coumaroyldopamine and N-caffeoyldopamine were the two most potent compounds, able to increase cAMP at the concentrations < 0.05 µM in U937 cells. The decreasing order of potency was N-coumaroyldopamine > N-caffeoyldopamine > N-feruloyldopamine > N-sinapoyldopamine > N-cinnamoyldopamine. Using ß2-specific antagonists (butoxamine and ICI 118551), N-coumaroyldopamine and N-caffeoyldopamine were found to increase cAMP via ß2-adrenoceptors in U937 cells. In producing cAMP in U937 cells, N-coumaroyldopamine and N-caffeoyldopamine were as potent as several well-known ß2-adrenoceptor agonists (salbutamol, procaterol, and fenoterol). These results indicate that N-coumaroyldopamine and N-caffeoyldopamine are potent compounds able to increase cAMP via ß2-adrenoceptors in U937 cells, and may have potential effects on human health.Park, J. B. N-Coumaroyldopamine and N-caffeoyldopamine increase cAMP via beta 2-adrenoceptors in myelocytic U937 cells.
Key Words: phytochemical cardiac disease ß-adrenoceptor agonist cocoa
This article has been cited by other articles:
![]() |
J. B. Park and N. Schoene Clovamide-Type Phenylpropenoic Acid Amides, N-Coumaroyldopamine and N-Caffeoyldopamine, Inhibit Platelet-Leukocyte Interactions via Suppressing P-Selectin Expression J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 813 - 819. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |